Pipes Feed Preview: ClinicalTrials.gov: COVID-19 | Last update posted in the last 14 days

  1. C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome

    Tue, 14 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: C11 ER176 Tracer <br/><b>Sponsors</b>: Mayo Clinic <br/><b>Not yet recruiting</b>

  2. Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS

    Tue, 14 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); ME/CFS Following COVID-19 <br/><b>Interventions</b>: Device: IA with TheraSorb ® column (Miltenyi) <br/><b>Sponsors</b>: Charite University, Berlin, Germany; German Federal Ministry of Research, Technology, and Space (BMFTR); Weidenhammer-Zöbele Foundation <br/><b>Recruiting</b>

  3. ME/CFS Brain Fog: Cognitive Rehabilitation Trial

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: ME/CFS; ME/CFS Following EBV-associated Infectious Mononucleosis; ME/CFS Following COVID-19; Chronic Fatigue; Chronic Fatigue Syndrome (CFS); Brain Fog; Cognitive Impairment; Cognitive Dysfunction <br/><b>Interventions</b>: Behavioral: Processing Speed Training; Behavioral: In-session Instrumental Activities of Daily Living Training; Behavioral: Transfer Package; Behavioral: Follow Up Phone Calls; Procedure: Trans-auricular Vagus Nerve Stimulation: High Intensity; Behavioral: In-session Brain Health Training; Behavioral: Reaction Time Training; Procedure: Trans-auricular Vagus Nerve Stimulation: Low Intensity <br/><b>Sponsors</b>: University of Alabama at Birmingham; UAB College of Arts and Sciences & Department of Psychology; Posit Science Corporation <br/><b>Not yet recruiting</b>

  4. PA-001 Ph.1 Study in Healthy and Elderly Subjects

    Thu, 09 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID - 19 <br/><b>Interventions</b>: Drug: PA-001 <br/><b>Sponsors</b>: PeptiDream Inc.; PeptiAID Inc. <br/><b>Completed</b>

  5. Noseguard for Prevention of Respiratory Infections in Real-World Use

    Wed, 08 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Respiratory Infection Virus; COVID-19; Influenza <br/><b>Interventions</b>: Device: Noseguard and Noseguard Night <br/><b>Sponsors</b>: Daewoong Pharmaceutical Co. LTD. <br/><b>Not yet recruiting</b>

  6. Lung Boost Trainer Versus Incentive Spirometer in Post COVID-19 Hemiplegic CP Children

    Mon, 06 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Post Covid-19; Hemiplegic; CP (Cerebral Palsy) <br/><b>Interventions</b>: Device: Lung boost trainer (LBT); Device: Incentive Spirometer Training ( IST); Other: Traditional Respiratory Physical Therapy Protocol (TRPT) <br/><b>Sponsors</b>: Cairo University <br/><b>Completed</b>

  7. The Effects of Operating Room COVID-19 Personal Protective Equipment on Speech Perception and Listening Effort

    Wed, 01 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Speech Perception; Communication Barriers; Operating Rooms; Protective Devices <br/><b>Sponsors</b>: Ondokuz Mayıs University <br/><b>Completed</b>

  8. Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

    Tue, 14 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Post-Acute COVID-19 Syndrome <br/><b>Interventions</b>: Drug: Keytruda <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Not yet recruiting</b>

  9. A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; SARS-COV-2 Infection <br/><b>Interventions</b>: Biological: BNT162b2 Vaccine; Biological: Placebo <br/><b>Sponsors</b>: BioNTech SE; Pfizer <br/><b>Active, not recruiting</b>

  10. Sonlicromanol in Post-COVID

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Post COVID Condition <br/><b>Interventions</b>: Drug: Sonlicromanol; Drug: Placebo <br/><b>Sponsors</b>: Michele van Vugt; ZonMw: The Netherlands Organisation for Health Research and Development; Khondrion BV <br/><b>Recruiting</b>

  11. A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: Aluminum Hydroxide Suspension; Biological: Boost-2867; Biological: CpG 7909; Other: Sodium Chloride, 0.9% <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Recruiting</b>

  12. Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Biological: PepGNP-COVID19; Other: Sterile Water for Injection <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Active, not recruiting</b>

  13. Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

    Tue, 14 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Respiratory Tract Infection; Smell Disorder; Influenza; Rhinosinusitis; COVID-19; Depression; Parosmia; Hyposomia; Normosomia; Anosmia <br/><b>Sponsors</b>: National Institute on Deafness and Other Communication Disorders (NIDCD) <br/><b>Not yet recruiting</b>

  14. Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers

    Wed, 01 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Healthy Volunteers <br/><b>Interventions</b>: Biological: CD40.Pan.CoV Low dose(0.25mg); Biological: CD40.Pan.CoV Low dose (0,25mg) adjuvanted with Hiltonol®; Biological: CD40.Pan.CoV High dose (1mg); Biological: CD40.Pan.CoV High dose (1mg) adjuvanted with Hiltonol® <br/><b>Sponsors</b>: ANRS, Emerging Infectious Diseases; Institut National de la Santé Et de la Recherche Médicale, France; Enno DC; Unité Mixte de Service 54 Methods and Applied Research for Trials (UMS 54 MART) <br/><b>Recruiting</b>

  15. Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults

    Tue, 14 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Biological: STX-S <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Active, not recruiting</b>

  16. A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection <br/><b>Interventions</b>: Drug: ibuzatrelvir; Drug: remdesivir; Drug: placebo for ibuzatrelvir; Drug: placebo for remdesivir <br/><b>Sponsors</b>: Pfizer <br/><b>Recruiting</b>

  17. Pancoronavirus Vaccine Study in Healthy Adults

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Respiratory Infection; SARS CoV 2 Infection; COVID-19 Vaccine <br/><b>Interventions</b>: Biological: CoV-RBD-scNP-001 and 3M-052-AF <br/><b>Sponsors</b>: Duke University; National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Active, not recruiting</b>

  18. Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

    Fri, 03 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID <br/><b>Interventions</b>: Drug: Pirfenidone; Drug: Placebo for pirfenidone; Drug: Upadacitinib; Drug: Placebo for upadacitinib <br/><b>Sponsors</b>: Douglas D. Fraser <br/><b>Recruiting</b>

  19. Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID-19 Syndrome; COVID 19; Noncommunicable Disease; Hypertension; Diabetes Mellitus; Long COVID <br/><b>Interventions</b>: Other: Functional and cognitive rehabilitation strategy; Other: Evidence-Based Informational Support <br/><b>Sponsors</b>: Fundación Cardioinfantil Instituto de Cardiología; Hospital Militar Central, Colombia <br/><b>Recruiting</b>

  20. Cognitive-Sensorimotor Function in Long-COVID

    Tue, 14 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Post-acute Sequelae of SARS-CoV-2 Infection <br/><b>Sponsors</b>: VA Office of Research and Development; Edward Hines Jr. VA Hospital <br/><b>Recruiting</b>

  21. Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)

    Fri, 03 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Post COVID-19 Condition; Long COVID Syndrome; Persistent COVID-19; Persistent COVID Condition; Long COVID <br/><b>Interventions</b>: Drug: Plitidepsin 1.5 mg/day; Drug: Placebo; Drug: Placebo and Plitidepsin 1.5mg/day <br/><b>Sponsors</b>: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia; PharmaMar; IrsiCaixa <br/><b>Recruiting</b>

  22. A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Coronavirus Disease (COVID-19) <br/><b>Interventions</b>: Drug: Molnupiravir; Drug: Placebo <br/><b>Sponsors</b>: Merck Sharp & Dohme LLC <br/><b>Recruiting</b>

  23. Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: PASC Post Acute Sequelae of COVID-19 <br/><b>Sponsors</b>: National Institute of Neurological Disorders and Stroke (NINDS) <br/><b>Recruiting</b>

  24. Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Post-COVID Postural Orthostatic Tachycardia Syndrome <br/><b>Interventions</b>: Biological: IgPro20; Biological: Placebo <br/><b>Sponsors</b>: CSL Behring <br/><b>Terminated</b>

  25. Improving Attention in Individuals With Long COVID-19

    Thu, 02 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Long Covid <br/><b>Interventions</b>: Other: Attention Training; Other: Music Group <br/><b>Sponsors</b>: Shirley Ryan AbilityLab <br/><b>Completed</b>

  26. Risk in Devel Long-COVID in Contracting SARS-CoV-2 Infection After COVID-19 Vaccination in Relation to Vitamin D3 Suppl

    Wed, 08 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Vitamin d Deficiency; COVID-19; Long COVID <br/><b>Sponsors</b>: IRCCS San Raffaele; Abiogen Pharma <br/><b>Completed</b>

  27. Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

    Thu, 02 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID; Post Acute Sequelae of COVID-19; Post-Acute COVID-19 <br/><b>Interventions</b>: Drug: Ensitrelvir; Other: Placebo <br/><b>Sponsors</b>: Timothy Henrich; Shionogi Inc. <br/><b>Active, not recruiting</b>

  28. A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID-19 Syndrome; Chronic Fatigue Syndrome <br/><b>Interventions</b>: Drug: Fluvoxamine Maleate 100 MG; Drug: Placebo; Drug: Metformin Extended Release Oral Tablet <br/><b>Sponsors</b>: Cardresearch <br/><b>Completed</b>

  29. Living With Long COVID: LONGCOVID-EXPERIENCE

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID; Experience, Life <br/><b>Sponsors</b>: Corporacion Parc Tauli; Universitat Autonoma de Barcelona <br/><b>Completed</b>

  30. Long COVID Brain Fog: Cognitive Rehabilitation Trial

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Long COVID; Brain Fog; Cognitive Impairment; Cognitive Dysfunction; Post-Acute COVID-19 Syndrome <br/><b>Interventions</b>: Behavioral: Processing Speed Training; Behavioral: In-lab Instrumental Activities of Daily Living Training; Behavioral: In-lab Brain Health Training; Behavioral: Transfer Package; Behavioral: Follow Up Phone Calls; Behavioral: Vocational Rehabilitation; Behavioral: Peer Mentoring; Behavioral: Reaction Time Training; Procedure: Trans-auricular Vagus Nerve Stimulation: High Intensity; Procedure: Trans-auricular Vagus Nerve Stimulation: Low Intensity <br/><b>Sponsors</b>: University of Alabama at Birmingham; National Institute on Disability, Independent Living, and Rehabilitation Research; Posit Science <br/><b>Recruiting</b>

  31. SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI

    Fri, 03 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Spinal Cord Injuries; Traumatic Spinal Cord Injury; Healthy Controls; Flu Vaccine; COVID-19 Vaccine <br/><b>Sponsors</b>: Northwell Health; United States Department of Defense; New York State Department of Health <br/><b>Active, not recruiting</b>

  32. Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)

    Thu, 02 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Smell Dysfunction; Olfactory Disorder; Long COVID <br/><b>Interventions</b>: Device: Trigeminal Nerve Stimulation (TNS); Other: Active Smell Training (ST); Other: Placebo Smell Training (PBO) <br/><b>Sponsors</b>: Medical University of South Carolina; National Institutes of Health (NIH); National Institute on Deafness and Other Communication Disorders (NIDCD) <br/><b>Recruiting</b>

  33. Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Covid-19 Pandemics; Tuberculosis <br/><b>Interventions</b>: Biological: Pfizer-BioNTech COVID-19 vaccine; Biological: AstraZeneca vaccine; Biological: Janssen Ad26.COV2.S COVID-19 vaccine <br/><b>Sponsors</b>: University of Oxford <br/><b>Recruiting</b>

  34. A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: SARS-CoV-2 Virus; Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19 <br/><b>Interventions</b>: Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose; Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose; Biological: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose; Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose; Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose; Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose; Biological: Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose <br/><b>Sponsors</b>: BioNTech SE; Pfizer <br/><b>Active, not recruiting</b>

  35. Antihistamines, Amantadine and Evolution of COVID-19

    Fri, 03 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Drug: Antihistamine; Drug: Amantadine <br/><b>Sponsors</b>: Consorci Sanitari de Terrassa; Institut Català de la Salut <br/><b>Recruiting</b>

  36. A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies in Prophylaxis and Curative of Covid-19 (COVIMAB)

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Immunocompromised Patients <br/><b>Interventions</b>: Other: Data collection <br/><b>Sponsors</b>: Assistance Publique - Hôpitaux de Paris; URC-CIC Paris Descartes Necker Cochin <br/><b>Completed</b>

  37. A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults

    Tue, 07 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Biological: Prime-2-CoV_Beta <br/><b>Sponsors</b>: University Hospital Tuebingen; FGK Clinical Research GmbH; VisMederi srl; Staburo GmbH; Viedoc Technologies AB <br/><b>Recruiting</b>

  38. COVID-19 Experiences in the SELF Cohort

    Tue, 14 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Sponsors</b>: National Institute of Environmental Health Sciences (NIEHS) <br/><b>Enrolling by invitation</b>

  39. Respiratory Virus Sampling and Repository

    Wed, 08 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Influenza; COVID-19 <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Recruiting</b>

  40. COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation

    Thu, 02 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Breast Cancer, NOS <br/><b>Interventions</b>: Other: Questionnaire <br/><b>Sponsors</b>: Eastern Cooperative Oncology Group <br/><b>Terminated</b>

  41. Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients

    Fri, 03 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; Immunosuppression; Vaccine Response Impaired <br/><b>Interventions</b>: Drug: Reduction in antimetabolite immunosuppression <br/><b>Sponsors</b>: University of California, Davis; CareDx <br/><b>Active, not recruiting</b>

  42. SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Covid19 <br/><b>Interventions</b>: Other: Standard of Care; Biological: SARS-CoV2-CTLS <br/><b>Sponsors</b>: New York Medical College; Children's Hospital of Philadelphia; Medical College of Wisconsin; Nationwide Children's Hospital <br/><b>Recruiting</b>

  43. The Impact of the COVID-19 Pandemic on Eating Behavior and Weight Change

    Wed, 08 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19; Obesity <br/><b>Sponsors</b>: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) <br/><b>Completed</b>

  44. BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers

    Fri, 03 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Healthy; Immunization; Infection <br/><b>Interventions</b>: Biological: 3 doses of BNT162b2 vaccine; Biological: 2 dose of BNT162b2 vaccine <br/><b>Sponsors</b>: ANRS, Emerging Infectious Diseases; Institut National de la Santé Et de la Recherche Médicale, France <br/><b>Completed</b>

  45. Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination

    Wed, 08 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Influenza; COVID-19 <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Recruiting</b>

  46. Thymic Function in Patients With COVID-19

    Wed, 08 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Covid19 <br/><b>Interventions</b>: Genetic: Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region; Biological: Blood sample; Diagnostic Test: CT Scan; Biological: Bronchial fibroscopy <br/><b>Sponsors</b>: CMC Ambroise Paré <br/><b>Completed</b>

  47. The Nanowear Wearable Covid-19 Observational and Analysis Trend

    Thu, 09 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Covid19 <br/><b>Interventions</b>: Device: Observational Study - no intervention <br/><b>Sponsors</b>: Nanowear Inc. <br/><b>Terminated</b>

  48. HEALthy Brain and Child Development Study - COVID-19 Supplement

    Mon, 06 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Child Development; Prenatal Infection; Prenatal Stress; Covid19 <br/><b>Interventions</b>: Other: No Intervention <br/><b>Sponsors</b>: Boston Children's Hospital; Brigham and Women's Hospital; Massachusetts General Hospital <br/><b>Completed</b>

  49. Remotely Delivered Programs Targeting COVID-19 Stress-Related Depression and Substance Use

    Tue, 07 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Depression; Anxiety; Substance Use; Stress, Psychological; Stress, Emotional; Alcohol Use, Unspecified; Drug Use; Covid19 <br/><b>Interventions</b>: Behavioral: Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell; Behavioral: Internet Cognitive Behavioral Therapy plus CHAMindWell; Behavioral: CHAMindWell <br/><b>Sponsors</b>: Cambridge Health Alliance; National Center for Complementary and Integrative Health (NCCIH); Penn State University <br/><b>Completed</b>

  50. Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

    Tue, 14 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection; COVID-19-Associated Acute Respiratory Distress Syndrome; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Symptomatic COVID-19 Infection Laboratory-Confirmed <br/><b>Interventions</b>: Other: Best Practice; Biological: Mesenchymal Stem Cell <br/><b>Sponsors</b>: M.D. Anderson Cancer Center; National Cancer Institute (NCI) <br/><b>Recruiting</b>

  51. Telerehabilitation in Oncology Patients

    Wed, 08 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Cancer Metastatic; Cancer; Survivorship <br/><b>Interventions</b>: Other: Therapeutic Exercise and Education <br/><b>Sponsors</b>: University of Malaga <br/><b>Completed</b>

  52. OPV as Potential Protection Against COVID-19

    Tue, 07 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Poliovirus Vaccine, Oral; COVID; Mortality; Morbidity; Non-Specific Effects of Vaccines <br/><b>Interventions</b>: Biological: oral polio vaccine + information; Behavioral: Information <br/><b>Sponsors</b>: Bandim Health Project <br/><b>Completed</b>

  53. Living With Sickle Cell Disease in the COVID-19 Pandemic

    Wed, 08 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Isolation; Anxiety; Health Care Utilization; Sickle Cell Disease; Pain <br/><b>Sponsors</b>: National Human Genome Research Institute (NHGRI) <br/><b>Completed</b>

  54. A Longitudinal Study of COVID-19 Sequelae and Immunity

    Tue, 14 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Sponsors</b>: National Institute of Allergy and Infectious Diseases (NIAID) <br/><b>Active, not recruiting</b>

  55. NCI COVID-19 in Cancer Patients, NCCAPS Study

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 Infection; Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm <br/><b>Interventions</b>: Procedure: Biospecimen Collection; Other: Data Collection; Other: Quality-of-Life Assessment; Other: Questionnaire Administration <br/><b>Sponsors</b>: National Cancer Institute (NCI) <br/><b>Active, not recruiting</b>

  56. ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers

    Wed, 08 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Covid-19; Coronavirus Infection; Coronavirus <br/><b>Interventions</b>: Other: COVID-19 Serology; Behavioral: Health Care Worker Survey <br/><b>Sponsors</b>: Columbia University <br/><b>Recruiting</b>

  57. Tocilizumab Treatment in Patients With COVID-19

    Thu, 09 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Sars-CoV2 <br/><b>Interventions</b>: Drug: Tocilizumab 20 MG/ML <br/><b>Sponsors</b>: Instituto Nacional de Cancerologia de Mexico; Roche Pharma AG <br/><b>Active, not recruiting</b>

  58. Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of COVID-19 Infection.

    Thu, 02 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: COVID-19 <br/><b>Interventions</b>: Biological: vaccine BCG; Other: Placebo <br/><b>Sponsors</b>: Universidad de Antioquia <br/><b>Withdrawn</b>

  59. Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers

    Wed, 01 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Healthy Volunteer; Mood Disorder; Anxiety Disorder; Preexisting Medical Condition <br/><b>Sponsors</b>: National Institute of Mental Health (NIMH) <br/><b>Completed</b>

  60. Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19

    Wed, 01 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: SARS (Severe Acute Respiratory Syndrome); Coronavirus <br/><b>Interventions</b>: Drug: Nitric Oxide Gas <br/><b>Sponsors</b>: Massachusetts General Hospital; Xijing Hospital; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Niguarda Hospital <br/><b>Completed</b>

  61. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    Mon, 06 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome <br/><b>Interventions</b>: Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: <br/><b>Sponsors</b>: Duke University; The Emmes Company, LLC; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) <br/><b>Recruiting</b>

  62. Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes

    Mon, 13 Apr 2026 04:00:00 -0000

    <b>Conditions</b>: Diabetes Mellitus, Type One; Diabetes Mellitus, Type I; Autoimmune Diabetes; Covid19 <br/><b>Interventions</b>: Biological: Bacillus Calmette-Guérin; Biological: Saline injection <br/><b>Sponsors</b>: Massachusetts General Hospital <br/><b>Active, not recruiting</b>